

***Fiscal Year 2020 Kidney Cancer Research Program  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Concept Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">W81XWH-20-KCRP-CA</a></p>	<p>All investigators at or above the level of postdoctoral fellow (or equivalent) are eligible.</p>	<ul style="list-style-type: none"> <li>• Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.</li> <li>• Emphasis on innovation.</li> <li>• <b><i>Clinical trials are not allowed.</i></b></li> <li>• <b><i>Preliminary data are not allowed.</i></b></li> <li>• <b><i>Blinded review.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding of <b>\$100,000</b> for direct costs (plus indirect costs).</li> <li>• Maximum period of performance is <b>1 year</b>.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> July 15, 2020 5:00 p.m. ET</p> <p><b>Application:</b> August 10, 2020 11:59 p.m. ET</p>

***Fiscal Year 2020 Kidney Cancer Research Program  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Academy of Kidney Cancer Investigators – Early-Career Investigator Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <u>W81XWH-20-KCRP-AKCIECIA</u></p>	<p>Must be within 3 years of their last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.) or equivalent as of the full application submission deadline.</p> <p><i>A letter attesting to eligibility is required.</i></p>	<ul style="list-style-type: none"> <li>• Supports the addition of new Early-Career Investigators to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.</li> <li>• Early-Career Investigators whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.</li> <li>• A Designated Mentor who is an experienced kidney cancer researcher with kidney cancer funding is required.</li> <li>• The Designated Mentor is not required to be at the same institution as the Early-Career Investigator.</li> <li>• <i>Preliminary data are required.</i></li> <li>• <i>Clinical trials are not allowed.</i></li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding of <b>\$725,000</b> for direct costs (plus indirect costs).</li> <li>• Maximum period of performance is <b>4 years</b>.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> August 26, 2020 5:00 p.m. Eastern time (ET)</p> <p><b>Application:</b> September 16, 2020 11:59 p.m. ET</p>
<p><b>Translational Research Partnership Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <u>W81XWH-20-KCRP-TRPA</u></p>	<p>The Initiating Principal Investigator (PI) must be at or above the level of Assistant Professor or equivalent.</p> <p>The Partnering PI must be at or above the level of Assistant Professor or equivalent.</p> <p><i>Postdoctoral fellows are not eligible to be Partnering PIs.</i></p>	<ul style="list-style-type: none"> <li>• Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.</li> <li>• Supports translational/correlative studies.</li> <li>• <i>Preliminary data are required.</i></li> <li>• <i>Clinical trials are not allowed.</i></li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding of <b>\$750,000</b> for direct costs (plus indirect costs).</li> <li>• Maximum period of performance is <b>3 years</b>.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> August 26, 2020 5:00 p.m. ET</p> <p><b>Application:</b> September 16, 2020 11:59 p.m. ET</p>

***Fiscal Year 2020 Kidney Cancer Research Program  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Clinical Consortium – Clinical Trial Site Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">W81XWH-20-KCRP-CTCA</a></p>	<p>Independent investigators at or above the level of Assistant Professor (or equivalent) are eligible.</p>	<ul style="list-style-type: none"> <li>• Supports the expansion of a consortium that will facilitate therapid execution of collaborative clinical trials that will bring to market high-impact, novel therapeutics that will ultimately and significantly decrease the impact of kidneycancer.</li> <li>• Funds may not be used for research or development of clinical protocols.</li> <li>• Trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction or aggressiveness, and/or progression of kidney cancer areencouraged.</li> <li>• Up to two Clinical Trial Sites will be selected and will be jointly responsible for proposing, selecting, and conducting trials within the existing Kidney Cancer ResearchConsortium.</li> <li>• Sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer.</li> <li>• The consortium is expected to achieve financial self-sufficiency, such that operations can continue after the award period ends.</li> </ul>	<p><b>Clinical Trial Sites</b></p> <ul style="list-style-type: none"> <li>• Maximum funding of <b>\$600,000</b> for direct costs (plus indirect costs).</li> <li>• Maximum period of performance is <b>2 years</b>.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> September 2, 2020 5:00 p.m. Eastern time (ET)</p> <p><b>Application:</b> September 23, 2020 11:59 p.m. ET</p>
<p><b>Idea Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">W81XWH-20-KCRP-IDA</a></p>	<p><b>Established Investigators:</b> Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or</p> <p><b>Early-Career Investigators:</b> Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10</p>	<ul style="list-style-type: none"> <li>• Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancerresearch, and have the potential to make an important contribution to kidney cancer.</li> <li>• Innovation and Impact are the most important reviewcriteria.</li> <li>• Different funding options, based on the scope of the proposed research, are available with compellingjustification.</li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding of <b>\$600,000</b> in direct costs (plus indirect costs).</li> <li>• Period of performance not to exceed <b>3 years</b>.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> September 2, 2020 5:00 p.m. ET</p> <p><b>Application:</b> September 23, 2020 11:59 p.m. ET</p>

***Fiscal Year 2020 Kidney Cancer Research Program  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
	<p>years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible.</p>	<ul style="list-style-type: none"> <li>• <i>Preliminary data are required.</i></li> <li>• <i>Clinical trials are not allowed.</i></li> </ul>	<p><b>Early Detection Studies Option:</b></p> <ul style="list-style-type: none"> <li>• Maximum funding of <b>\$650,000</b> in direct costs (plus indirect costs).</li> <li>• Period of performance not to exceed <b>3 years</b>.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul> <p><b>Population Science and Prevention Studies Option:</b></p> <ul style="list-style-type: none"> <li>• Maximum funding of <b>\$2 million</b> in direct costs (plus indirect costs).</li> <li>• Period of performance not to exceed <b>4 years</b>.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	
<p><b>Postdoctoral and Clinical Fellowship Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">W81XWH-20-KCRP-PCFA</a></p>	<p>Must have completed requirements for a Ph.D. and/or M.D.</p> <p>Must be in the laboratory or clinical setting where proposed research will be performed.</p> <p>Must have no more than 4 years of postdoctoral and/or mentored clinical research experience.</p> <p><i>Investigators in non-postdoctoral and/or clinical fellow positions are not eligible.</i></p>	<ul style="list-style-type: none"> <li>• Supports research opportunities focused on kidney cancer for individuals in the early stages of their careers</li> <li>• A designated Mentor who is an experienced kidney cancer researcher is required.</li> <li>• <i>Clinical trials are not allowed.</i></li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding of <b>\$195,000</b> for direct costs (plus indirect costs).</li> <li>• Maximum period of performance is <b>3 years</b>.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> September 2, 2020 5:00 p.m. ET</p> <p><b>Application:</b> September 23, 2020 11:59 p.m. ET</p>

***Fiscal Year 2020 Kidney Cancer Research Program  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Clinical Research Nurse Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">W81XWH-20-KCRP-CRNDA</a></p>	<p>The Initiating Principal Investigator (PI) must be at or above the level of Assistant Professor (or equivalent) with an M.D. and/or M.D./Ph.D. degree (or equivalent).</p> <p>The Partnering PI must be a <b><i>clinical research nurse coordinator (or equivalent)</i></b> with at least 2 years of oncology or cancer clinical trial research nurse experience, and have a Registered Nurse license and/or a Bachelor's, Master's, or Doctoral degree in nursing.</p>	<ul style="list-style-type: none"> <li>• Supports partnerships between a clinician and a clinical research nurse coordinator (or equivalent).</li> <li>• Supports kidney cancer research and the career development of kidney cancer clinical trial research nurses.</li> <li>• <b><i>Clinical trials are not allowed; correlative studies to clinical trials are allowed.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding of <b>\$300,000</b> for direct costs (plus indirect costs).</li> <li>• Maximum period of performance is <b>2 years</b>.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> October 13, 2020 5:00 p.m. ET</p> <p><b>Application:</b> November 3, 2020 11:59 p.m. ET</p>